Refractory Pseudomonas aeruginosa Bronchopulmonary Infection After Lung Transplantation for Common Variable Immunodeficiency Despite Maximal Treatment Including IgM/IgA-Enriched Immunoglobulins and Bacteriophage Therapy
Abstract
Recipients transplanted for bronchiectasis in the context of a primary immune deficiency, such as common variable immunodeficiency, are at a high risk of severe infection in post-transplantation leading to poorer long-term outcomes than other transplant indications. In this report, we present a fatal case due to chronic Pseudomonas aeruginosa bronchopulmonary infection in a lung transplant recipient with common variable immunodeficiency despite successful eradication of an extensively drug-resistant (XDR) strain with IgM/IgA-enriched immunoglobulins and bacteriophage therapy. The fatal evolution despite a drastic adaptation of the immunosuppressive regimen and the maximal antibiotic therapy strategy raises the question of the contraindication of lung transplantation in such a context of primary immunodeficiency. Keywords: primary immunodeficiency diseases, lung transplantation, Pseudomonas aeruginosa , phage therapy, immunoglobulin therapy
Related
- Bacteriophage PAK_P3 genome structuration and dynamics during infection of Pseudomonas aeruginosa reveal specific interaction patterns
- The bacteriophage transcription factor Gp53 suppresses cell division and regulates Pseudomonas aeruginosa physiology
- A dual-action bacteriophage protein Ped1 degrades DNA and blocks replication in Pseudomonas aeruginosa
- Bacteriophage and Antibiotic Resistance Are Positively Associated across a Phylogenetically Diverse Set of Clinical Pseudomonas aeruginosa Isolates
- Bacteriophage Therapy in Cystic Fibrosis: Emerging Strategies for Managing Chronic Pseudomonas aeruginosa Infections.
BibTeX
@article{leveque2026refractory,
title = {{Refractory Pseudomonas aeruginosa Bronchopulmonary Infection After Lung Transplantation for Common Variable Immunodeficiency Despite Maximal Treatment Including IgM/IgA-Enriched Immunoglobulins and Bacteriophage Therapy}},
author = {Manon Levêque and Nadim Cassir and Fanny Mathias and Cindy Fevre and Florence Daviet and Julien Bermudez and Geoffrey Brioude and Florence Peyron and Martine Reynaud-Gaubert and Benjamin Coiffard},
journal = {Infection and Drug Resistance},
year = {2026},
month = oct,
doi = {10.2147/idr.s413900},
url = {https://hal.science/hal-05795768v1},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Refractory Pseudomonas aeruginosa Bronchopulmonary Infection After Lung Transplantation for Common Variable Immunodeficiency Despite Maximal Treatment Including IgM/IgA-Enriched Immunoglobulins and Bacteriophage Therapy
AU - Manon Levêque
AU - Nadim Cassir
AU - Fanny Mathias
AU - Cindy Fevre
AU - Florence Daviet
AU - Julien Bermudez
AU - Geoffrey Brioude
AU - Florence Peyron
AU - Martine Reynaud-Gaubert
AU - Benjamin Coiffard
PY - 2026
DA - 2026/10/12
JO - Infection and Drug Resistance
DO - 10.2147/idr.s413900
UR - https://hal.science/hal-05795768v1
AB - Recipients transplanted for bronchiectasis in the context of a primary immune deficiency, such as common variable immunodeficiency, are at a high risk of severe infection in post-transplantation leading to poorer long-term outcomes than other transplant indications. In this report, we present a fatal case due to chronic Pseudomonas aeruginosa bronchopulmonary infection in a lung transplant recipient with common variable immunodeficiency despite successful eradication of an extensively drug-resistant (XDR) strain with IgM/IgA-enriched immunoglobulins and bacteriophage therapy. The fatal evolution despite a drastic adaptation of the immunosuppressive regimen and the maximal antibiotic therapy strategy raises the question of the contraindication of lung transplantation in such a context of primary immunodeficiency. Keywords: primary immunodeficiency diseases, lung transplantation, Pseudomonas aeruginosa , phage therapy, immunoglobulin therapy
SN - 1178-6973
ER -